Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Majority of population overweight/obese by 2035

<< Previous

Bullboard Posts

Next >>

Comment by houbahopon Mar 04, 2023 8:22pm

96 Views

Post# 35319639

RE:RE:Majority of population overweight/obese by 2035

This scarlet poster will continue to throw smoke until the stock trades to zero.
Even then, he will probably continue to post until this forum is shut down.
So much time spent pumping science on this forum. Valuable some time in the past, it has now become pathetic.

<< Previous

Bullboard Posts

Next >>

E3 inches closer to Alberta's first lithium production plant